Rivastigmine Tartrate Capsule
Product Images NDC 0904-7107

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Rivastigmine Tartrate (NDC 0904-7107). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton Label (39aadc39 0f4f 44f7 88de 83a0ea2ac332 00)

Rivastigmine Tartrate Capsules, USP 1.5 mg unit dose carton label from Major Pharmaceuticals. The label states Rx only and contains 100 capsules. It includes storage instructions and warnings. The label shows the NDC 0904-7107-61 and is distributed by Major Pharmaceuticals, Livonia, MI.*

FDA Label Image

Figure 1 (Rivastigmine Fig1)

A line graph titled 'Time-course of the Change from Baseline in ADAS-cog Score for Patients Completing 26 Weeks of Treatment in Study 1.' It shows mean change from baseline ADAS-cog rating (with error bars) on the vertical axis versus weeks during treatment (0, 12, 18, 26) on the horizontal axis. Three lines represent different groups: 6 to 12 mg, 1 to 4 mg, and placebo. The 6 to 12 mg group trends toward clinical improvement, while the other groups show clinical decline over the treatment period.*

FDA Label Image

Figure 2 (Rivastigmine Fig2)

A line graph showing cumulative percentage of patients completing 26 weeks of double-blind treatment with change in ADAS-cog scores from baseline. The graph compares three groups: placebo, 1 to 4 mg/day, and 6 to 12 mg/day, with lines representing cumulative patient percentages vs. change from baseline. A table summarizes the treatment groups' ADAS-cog score changes at -7, -4, and 0 points.*

FDA Label Image

Figure 3 (Rivastigmine Fig3)

A bar chart illustrating the frequency distribution of CIBIC-Plus scores at Week 26 in Study 1, comparing Placebo, 1 to 4 mg, and 6 to 12 mg groups. The x-axis shows CIBIC-Plus ratings from Markedly Improved to Markly Worse, and the y-axis shows the percentage of patients. Different bars represent the treatment groups for each rating category.*

FDA Label Image

Fig-4 (Rivastigmine Fig4)

A line graph titled 'Time-course of the Change from Baseline in ADAS-cog Score for Patients Completing 26 Weeks of Treatment' shows mean changes in ADAS-cog rating over 26 weeks for three groups: 6 to 12 mg, 1 to 4 mg, and placebo. The Y-axis measures mean change from baseline, ranging from -3 to 2, with negative values indicating clinical improvement and positive values clinical decline. The 6 to 12 mg group shows a trend toward clinical improvement, while 1 to 4 mg and placebo groups trend toward clinical decline.*

FDA Label Image

Fig-5 (Rivastigmine Fig5)

A cumulative percentage graph showing patients completing 26 weeks of double-blind treatment with changes from baseline ADAS-cog scores. The graph compares three groups: 6 to 12 mg, 1 to 4 mg, and placebo. It includes a table of treatment groups with corresponding ADAS-cog score changes at -7, -4, and 0 points, illustrating cognitive score improvement over time.*

FDA Label Image

Figure 6 (Rivastigmine Fig6)

A bar chart showing the frequency distribution of CIBIC-Plus scores at week 26 in Study 2. The categories on the x-axis include Markedly Improved, Moderately Improved, Minimally Improved, Unchanged, Minimally Worse, Moderately Worse, and Markedly Worse. The y-axis represents the percentage of patients. Data is presented for three groups: Placebo, 1 to 4 mg, and 6 to 12 mg.*

FDA Label Image

Figure 7 (Rivastigmine Fig7)

Line graph showing the time course of change from baseline in ADAS-cog scores over 24 weeks of treatment. The graph compares Rivastigmine Tartrate and placebo groups, with the y-axis representing mean change in ADAS-cog rating and the x-axis representing weeks during treatment. Error bars indicate variability, highlighting clinical improvement with Rivastigmine Tartrate versus placebo.*

FDA Label Image

Figure 8 (Rivastigmine Fig8)

A bar chart showing the distribution of ADCS-CGIC scores for patients completing 24 weeks of treatment in Study 4. The x-axis represents ADCS CGI-C ratings ranging from 'Markedly Improved' to 'Markedly Worse,' and the y-axis shows the percentage of patients. Two groups are compared: Rivastigmine Tartrate and Placebo, with respective bars indicating the percentage of patients for each rating category.*

FDA Label Image

Chemical Structure (Rivastigmine Str)

Chemical structure of Rivastigmine Tartrate showing its molecular components including the tartrate salt representation.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.